HTG Molecular Diagnostics Profit Margin

HTG Molecular Diagnostics's profit margin stands at -324.28% as of March 2023. That compares with -216.6% in the prior-year period — down 49.7% year over year. That is below the Healthcare sector average of 15.58%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

HTG Molecular Diagnostics reported -324.28% in profit margin versus -216.6% a year earlier — a 49.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

HTG Molecular Diagnostics sits lower the Healthcare benchmark (15.58%) with a profit margin of -324.28%. That is roughly 2180.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -324.28% for HTG Molecular Diagnostics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how HTG Molecular Diagnostics's profit margin evolved across reporting periods, while the comparison chart places HTGM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.